TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems of the aging motor system, not muscle alone. Its authors say nerves, the brain, balance and movement control may contribute, but proposed additional clinical measures have not yet been shown to improve outcomes or reduce costs.
Researchers writing in The Lancet Healthy Longevity have proposed reframing sarcopenia—the age-related loss of strength and physical function—as a condition of the whole motor system, not just declining muscle. The argument could affect how clinicians assess weakness and mobility, but the authors say their suggested tests and approach still need validation.
The authors say the clinical definition of sarcopenia has already moved beyond muscle size. Measures such as grip strength, walking speed and chair stands are used because they predict outcomes including falls and disability better than muscle mass alone. However, the paper argues that explanations and treatment approaches have continued to focus heavily on muscle.
According to the authors, muscle loss accounts for only a modest share of the decline in strength seen with aging, and people with similar amounts of muscle can have different levels of strength and mobility. They point to a mismatch in research and treatment: some interventions can increase muscle without producing comparable gains in everyday function, while exercise can improve strength and mobility without measurable increases in muscle mass.
The paper describes the motor system as the brain, spinal cord, nerves and their connections with muscle, along with the systems involved in balance and sensing body position. Age-related changes across these areas may affect how quickly and reliably movement commands reach muscles. The authors argue that this helps explain why tasks requiring speed and coordination, such as rising from a chair, may become difficult even when muscle bulk alone does not explain the change.
A Wider View of Mobility Decline
A broader model could change what clinicians look for when an older person reports weakness. The authors suggest considering not only strength and walking speed but also how quickly someone stands from a chair, whether they become unsteady during sustained effort, and whether hand dexterity or walking changes when a second task is added, such as conversation.
The proposal also has implications for treatment and research priorities. If weakness can result from several parts of the motor system, interventions focused mainly on increasing muscle mass may not address every cause of impaired function. The authors argue for studies and care strategies that measure nerve function and everyday movement alongside muscle, with the goal of better identifying individual needs and supporting independence.
The public-health stakes are substantial, particularly in Australia, where the report says falls remain the leading cause of injury-related hospitalization and death. It cites 253,800 fall-related hospitalizations in 2024–25 and 6,722 deaths following falls in the preceding year. Those figures describe the Australian burden; they do not show that the proposed motor-system model or assessment changes would reduce falls.
Products Worth Considering
BowFlex Results Series SelectTech 552 Adjustable Dumbbell
Bowflex SelectTech 840 Adjustable Kettlebell
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
As an affiliate, we earn on qualifying purchases.
From Muscle Mass to Function
Sarcopenia is associated with loss of muscle, strength and physical function as people age. The report says it affects up to 29% of older adults living in the community, with higher rates in hospitals and residential elder care, as well as among people with frailty or multiple health conditions. It is linked to disability and loss of independence, though not every older adult with weakness has the same cause.
Earlier in 2026, the Australian Journal of General Practice published a proposed algorithm to guide primary-care screening, assessment and management of poor muscle health. The new paper, by Lucas B. R. Orssatto and colleagues, takes up the question of what clinicians should be assessing when patients become weaker or slower. It sets out a five-point agenda for international groups that develop diagnostic criteria, seeking changes in how sarcopenia is defined and studied.
The authors also note that medications can affect motor drive. They identify sedative and anticholinergic medicines as possible contributors to reduced motor function and say medication review should be considered alongside strength training. This is a proposal for clinical assessment, not a recommendation for patients to stop or change prescribed medicines on their own.
“We propose that sarcopenia is better understood as a disease of the aging motor system.”
— Lucas B. R. Orssatto and colleagues, in their paper in The Lancet Healthy Longevity
Tests and Benefits Still Unproven
The paper advances a framework and research agenda; it does not establish that the proposed motor-system assessment is more accurate or useful than existing screening. The authors say the suggested measures have not been shown to improve outcomes or reduce costs. It is also unclear which practical tests would best identify changes in nerve function, movement control or balance in routine primary care.
The report does not provide trial evidence that adopting the framework would prevent falls, preserve independence or make treatments more effective. Access to neuromuscular expertise also varies across primary care settings, the authors say. More research will be needed to determine which patients benefit from additional assessment and how findings should guide care.
Validation Before Clinical Change
The authors call for investment in research to validate practical tests that clinicians can use, guidelines that support a staged assessment approach, and clinical trials measuring both nerve and muscle outcomes. International working groups responsible for diagnostic criteria are among those asked to consider the proposed five-point agenda.
Until tests and approaches are evaluated, the paper should be read as a call to broaden research and clinical attention—not evidence that current diagnostic criteria or care should be replaced. The next key developments will be studies comparing the proposed measures with existing screens and testing whether a wider assessment leads to better function, fewer falls or other meaningful benefits.
Key Questions
What is sarcopenia?
Sarcopenia refers to age-related loss of muscle, strength and physical function. The paper argues that weakness associated with it may involve more than muscle tissue alone.
What does the paper mean by the motor system?
The authors use the term for the systems involved in producing movement, including the brain, spinal cord, nerves and muscles, as well as balance and the sensing of body position.
Does the paper prove that the new approach improves mobility?
No. It proposes a broader way to understand sarcopenia and calls for further research. The authors say the suggested measures have not yet been shown to outperform existing screening on health outcomes or cost.
What might clinicians assess under the proposed approach?
In addition to strength and walking speed, the authors suggest examining the speed of standing from a chair, steadiness during sustained effort, hand dexterity and changes in walking while doing another task. These suggestions require further validation.
What should patients do about medicines mentioned in the report?
The authors say medication review may be relevant because some sedative and anticholinergic medicines can affect motor drive. Patients should discuss concerns with a qualified health professional and should not change prescribed medicines without medical guidance.
Source: rss
